Related Experiment Videos
Selective metabolic and hepatic biochemical alterations in breast cancer patients receiving different treatment
Ahmed M Amshawee1, Maggie E Amer2, Mena Mahfouz3
1ZOOLOGY DEPARTMENT, FACULTY OF SCIENCE, MANSOURA UNIVERSITY, MANSOURA, EGYPT; COLLEGE OF HEALTH AND MEDICAL TECHNOLOGY, UNIVERSITY OF HILLA, BABYLON, IRAQ.
Objective:
Aim: To study biochemical changes in women with breast cancer according to treatment protocols, with emphasis on liver and metabolic markers.
Patients And Methods:
Materials and Methods: A descriptive comparative cross-sectional study of 141 women including chemotherapy only (n=50), newly diagnosed n=46 and chemotherapy + metformin n=45 was conducted. The glucose, albumin, ALP, AST, ALT, creatinine and total bilirubin were determined in venous samples of blood by standard enzymatic methods. Data were presented as mean±SD and analyzed with one-way ANOVA.
Results:
Results: Glucose and ALP levels were significantly different. Compared with chemotherapy-only (86.38±15.96 mg/dL) and newly diagnosed groups, increased glucose (197.15±58.15 mg/dL) in the chemotherapy + metformin group p<0.001. Higher ALP was also noted in the metformin group (127.35±58.88 U/L) compared with chemotherapy alone (105.02±30.96 U/L) and newly diagnosed patients (108.81±40.84 U/L), p=0.039. Albumin, AST, ALT, creatinine and total bilirubin were not statistically different. AST was moderately correlated with ALT (r=0.524) and strongly correlated with total bilirubin r=0.752, p<0.001.
Conclusion:
Conclusions: The consumption of breast cancer therapy caused metabolic changes especially on glucose and ALP. Normal biochemical markers are still useful in surveillance for metabolic derangements due to treatment.
